The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks
Open accessAbstract
Endocannabinoid (eCB) signaling has been identified as a modulator of adaptation to stress, and is integral to basal and stress-induced glucocorticoid regulation. Furthermore, interactions between eCBs and glucocorticoids have been shown to be necessary for the regulation of emotional memories, suggesting that eCB function may relate to the development of post-traumatic stress disorder (PTSD). To examine this, plasma eCBs were measured in a sample (n=46) drawn from a population-based cohort selected for physical proximity to the World Trade Center (WTC) at the time of the 9/11 attacks. Participants received a structured diagnostic interview and were grouped according to whether they met diagnostic criteria for PTSD (no PTSD, n=22; lifetime diagnosis of PTSD=24). eCB content (2-arachidonoylglycerol (2-AG) and anandamide (AEA)) and cortisol were measured from 8 a.m. plasma samples. Circulating 2-AG content was significantly reduced among individuals meeting diagnostic criteria for PTSD. The effect of reduced 2-AG content in PTSD remained significant after controlling for the stress of exposure to the WTC collapse, gender, depression and alcohol abuse. There were no significant group differences for AEA or cortisol levels; however, across the whole sample AEA levels positively correlated with circulating cortisol, and AEA levels exhibited a negative relationship with the degree of intrusive symptoms within the PTSD sample. This report shows that PTSD is associated with a reduction in circulating levels of the eCB 2-AG. Given the role of 2-AG in the regulation of the stress response, these data support the hypothesis that deficient eCB signaling may be a component of the glucocorticoid dysregulation associated with PTSD. The negative association between AEA levels and intrusive symptoms is consistent with animal data indicating that reductions in AEA promote retention of aversive emotional memories. Future work will aim to replicate these findings and extend their relevance to clinical pathophysiology, as well as to neuroendocrine and molecular markers of PTSD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AEA levels have been shown to be reduced in PTSD patients (Hill et al., 2013;Neumeister et al., 2013) and depressed patients with high anxiety scores (Hill, Miller, Carrier, Gorzalka, & Hillard, 2009;Hill, Miller, Ho, Gorzalka, & Hillard, 2008).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Hill et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Reliability and validity of a brief instrument for assessing post-traumatic stress disorder
Foa, E. B., Riggs, D. S., Dancu, C. V., & Rothbaum, B. O. (1993) · Journal of Traumatic Stress · doi:10.1002/jts.2490060405 · Cited by 2,537
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Di, S., Malcher‐Lopes, R., Halmos, K. C., & Tasker, J. G. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04850.2003 · Cited by 820
Breslau, N., Davis, G. C., Peterson, E. L., & Schultz, L. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00933-1 · Cited by 582
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475
Self-citationStructured Clinical Interview for DSM-IV (SCID)
Kübler, U. (2013) · Springer eBooks · doi:10.1007/978-1-4419-1005-9_66 · Cited by 445
Status of Glucocorticoid Alterations in Post‐traumatic Stress Disorder
Yehuda, R. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04979.x · Cited by 409
Self-citationEnhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
Cited by
Sorted by citations
Post-traumatic stress disorder.
Yehuda, R., Hoge, C. W., McFarlane, A. C., Vermetten, E., Lanius, R. A., Nievergelt, C. M., Hobfoll, S. E., Koenen, K. C., Neylan, T. C., & Hyman, S. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.57 · Cited by 870
Self-citationNeurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 698
Self-citationPractical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
Hillard, C. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.130 · Cited by 449
Self-citationHill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 250
Self-citationSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
Self-citationThe Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development
Meyer, H. C., Lee, F. S., & Gee, D. G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.143 · Cited by 238
Understanding resilience: New approaches for preventing and treating PTSD
Horn, S. R. G.-V., Charney, D. S., & Feder, A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.07.002 · Cited by 240
Mayo, L. M., Asratian, A., Lindé, J., Morena, M., Haataja, R., Hammar, V., Augier, G., Hill, M. N., & Heilig, M. A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.034 · Cited by 216
Self-citationMichopoulos, V., Norrholm, S. D., & Jovanovic, T. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.01.005 · Cited by 206
Russo, E. B. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0009 · Cited by 193
Cameron, C., Watson, D. B., & Robinson, J. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000180 · Cited by 179
Bluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157
Shonesy, B. C., Bluett, R. J., Ramikie, T. S., Báldi, R., Hermanson, D. J., Kingsley, P. J., Marnett, L. J., Winder, D. G., Colbran, R. J., & Patel, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.001 · Cited by 155
Bowers, M. E., & Ressler, K. J. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.008 · Cited by 155
Stress-induced blood brain barrier disruption: Molecular mechanisms and signaling pathways
Welcome, M. O., & Mastorakis, N. E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104769 · Cited by 139
Endocannabinoid signalling modulates susceptibility to traumatic stress exposure
Bluett, R. J., Báldi, R., Haymer, A., Gaulden, A. D., Hartley, N. D., Parrish, W. P., Baechle, J. J., Marcus, D. J., Bey, R. M., Shonesy, B. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14782 · Cited by 140
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 146
Locci, A., & Pinna, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13843 · Cited by 132
Cannabis Therapeutics and the Future of Neurology
Russo, E. B. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00051 · Cited by 137
McLaughlin, R. J., Hill, M. N., & Gorzalka, B. B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.006 · Cited by 142
Self-citationJowf, G. I. A., Ahmed, Z. T., Reijnders, R. A., de Nijs, L., & Eijssen, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065238 · Cited by 145
Animal models for posttraumatic stress disorder: An overview of what is used in research
Borghans, B. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i4.387 · Cited by 120
Endocannabinoid concentrations in hair are associated with PTSD symptom severity
Wilker, S., Pfeiffer, A., Elbert, T. R., Ovuga, E., Karabatsiakis, A., Krumbholz, A., Thieme, D., Schelling, G., & Kolassa, I. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.010 · Cited by 116
Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 120
Self-citationAnimal models of post-traumatic stress disorder and recent neurobiological insights
Whitaker, A. M., Gilpin, N. W., & Edwards, S. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000069 · Cited by 110
Bedse, G., Hartley, N. D., Neale, E., Gaulden, A. D., Patrick, T. A., Kingsley, P. J., Uddin, M. J., Plath, N., Marnett, L. J., & Patel, S. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.002 · Cited by 108
A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome
Bowles, N. P., Karatsoreos, I. N., Li, X., Vemuri, K. V., Wood, J.-A., Li, Z., Tamashiro, K. L., Schwartz, G. J., Makriyannis, A., Kunos, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421420112 · Cited by 111
Self-citationSpagnolo, P. A., Ramchandani, V. A., Schwandt, M. L., Kwako, L. E., George, D. T., Mayo, L. M., Hillard, C. J., & Heilig, M. A. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13210 · Cited by 112
Self-citationCannabinoid Regulation of Fear and Anxiety: an Update
Papagianni, E. P., & Stevenson, C. W. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1026-z · Cited by 108
Emotional Modulation of Learning and Memory: Pharmacological Implications
LaLumiere, R. T., McGaugh, J. L., & McIntyre, C. K. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013474 · Cited by 103
Wolf, O. T., Atsak, P., de Quervain, D. J. ‐., Roozendaal, B., & Wingenfeld, K. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12353 · Cited by 101
de Bitencourt, R. M., & Takahashi, R. N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00502 · Cited by 108
Mayo, L. M., Rabinak, C. A., Hill, M. N., & Heilig, M. A. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.07.019 · Cited by 95
Self-citationKim, Y., Amidfar, M., & Won, E. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.008 · Cited by 96
Exercise as a Positive Modulator of Brain Function
Alkadhi, K. A. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0516-4 · Cited by 93
Atsak, P., Hauer, D., Campolongo, P., Schelling, G., Fornari, R. V., & Roozendaal, B. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.334 · Cited by 85
Genetics of glucocorticoid regulation and posttraumatic stress disorder -what do we know?
Castro-Vale, I., van Rossum, E. F. C., Machado, J. C., Mota-Cardoso, R., & Carvalho, D. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.005 · Cited by 85
Short overview on metabolomic approach and redox changes in psychiatric disorders
Erjavec, G. N., Konjevod, M., Perković, M. N., Štrac, D. Š., Tudor, L., Barbas, C., Grune, T., Žarković, N., & Pivac, N. (2017) · Redox Biology · doi:10.1016/j.redox.2017.09.002 · Cited by 82
Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity
Segev, A., Korem, N., Zer‐Aviv, T. M., Abush, H., Lange, R., Sauber, G., Hillard, C. J., & Akirav, I. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0135-4 · Cited by 81
Self-citationThe endocannabinoid system in mental disorders: Evidence from human brain studies
Ibarra‐Lecue, I., Pilar-Cuéllar, F., Muguruza, C., Florensa-Zanuy, E., Díaz, Á., Urigüen, L., Castro, E., Pazos, Á., & Callado, L. F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.009 · Cited by 84
Berardi, A., Schelling, G., & Campolongo, P. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.024 · Cited by 77
Endocannabinoids: Effectors of glucocorticoid signaling
Balsevich, G., Petrie, G. N., & Hill, M. N. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.07.005 · Cited by 82
Self-citationCannabinoid interventions for PTSD: Where to next?
Ney, L. J., Matthews, A. J., Bruno, R., & Felmingham, K. L. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.017 · Cited by 77
Neumeister, A., Seidel, J., Ragen, B., & Pietrzak, R. H. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.10.012 · Cited by 76
Bedse, G., Hill, M. N., & Patel, S. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.015 · Cited by 78
Self-citationFinding translation in stress research
Hariri, A. R., & Holmes, A. (2015) · Nature Neuroscience · doi:10.1038/nn.4111 · Cited by 83
A Systematic Review and Meta-Analysis on the Effects of Exercise on the Endocannabinoid System
Desai, S., Borg, B. A., Cuttler, C., Crombie, K. M., Rabinak, C. A., Hill, M. N., & Marusak, H. A. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0113 · Cited by 73
Self-citationVoegel, C. D., Baumgartner, M. R., Kræmer, T., Wüst, S., & Binz, T. M. (2020) · Talanta · doi:10.1016/j.talanta.2020.121499 · Cited by 69
Endocannabinoids and Mental Disorders
Rubino, T., Zamberletti, E., & Parolaro, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_9 · Cited by 72
Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD
Fidelman, S., Zer‐Aviv, T. M., Lange, R., Hillard, C. J., & Akirav, I. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.02.004 · Cited by 69
Self-citationDevelopmental regulation of fear learning and anxiety behavior by endocannabinoids
Lee, T. T.-Y., Hill, M. N., & Lee, F. S. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12253 · Cited by 71
Self-citationdeRoon‐Cassini, T. A., Bergner, C., Chesney, S. A., Schumann, N. R., Lee, T. S., Brasel, K. J., & Hillard, C. J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01808-1 · Cited by 65
Self-citationNey, L. J., Matthews, A. J., Bruno, R., & Felmingham, K. L. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.006 · Cited by 70
The Molecular Basis of Resilience: A Narrative Review
Ryan, M., & Ryznar, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.856998 · Cited by 65
Haney, M., & Evins, A. E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.251 · Cited by 67
Psychobiological Responses to Aerobic Exercise in Individuals With Posttraumatic Stress Disorder
Crombie, K. M., Brellenthin, A. G., Hillard, C. J., & Koltyn, K. F. (2018) · Journal of Traumatic Stress · doi:10.1002/jts.22253 · Cited by 68
Self-citationSeidemann, R., Duek, O. A., Jia, R., Levy, I., & Harpaz‐Rotem, I. (2021) · Chronic Stress · doi:10.1177/2470547021996006 · Cited by 69
Crombie, K. M., Leitzelar, B. N., Brellenthin, A. G., Hillard, C. J., & Koltyn, K. F. (2019) · Biological Psychology · doi:10.1016/j.biopsycho.2019.04.002 · Cited by 64
Self-citationRaber, J., Arzy, S., Bertolus, J. B., Depue, B., Haas, H. E., Hofmann, S. G., Kangas, M., Kensinger, E., Lowry, C. A., Marusak, H. A., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.015 · Cited by 62
Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD
Ney, L. J., Akhurst, J., Bruno, R., Laing, P. A. F., Matthews, A. J., & Felmingham, K. L. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110118 · Cited by 62
Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder
LaFrance, E. M., Glodosky, N. C., Bonn‐Miller, M. O., & Cuttler, C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.132 · Cited by 59
Gao, W., Walther, A., Wekenborg, M., Penz, M. S., & Kirschbaum, C. (2020) · Talanta · doi:10.1016/j.talanta.2020.121006 · Cited by 58
The Endocannabinoid System and Anxiety
Lisboa, S. F. D. S., Gomes, F. V., Terzian, A. L. B., de Aguiar, D. C., Moreira, F. A., Resstel, L. B. M., & Guimarães, F. S. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.09.006 · Cited by 56
Kamal, B., Kamal, F., & Lantela, D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00730 · Cited by 59
Therapeutic Challenges of Post-traumatic Stress Disorder: Focus on the Dopaminergic System
Torrisi, S. A., Leggio, G. M., Drago, F., & Salomone, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00404 · Cited by 59
Metabolite profiling in posttraumatic stress disorder
Karabatsiakis, A., Hamuni, G., Wilker, S., Kolassa, S., Renu, D., Kadereit, S., Schauer, M., Hennessy, T., & Kolassa, I. (2015) · Journal of Molecular Psychiatry · doi:10.1186/s40303-015-0007-3 · Cited by 53
Yi, B., Ничипорук, И. А., Nicolas, M., Schneider, S., Feuerecker, M., Vassilieva, G. Y., Thieme, D., Schelling, G., & Choukèr, A. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.004 · Cited by 51
The Neuroscience of Resilience
Hunter, R. G., Gray, J. D., & McEwen, B. S. (2018) · Journal of the Society for Social Work and Research · doi:10.1086/697956 · Cited by 60
Self-citationFluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids
Gunduz‐Cinar, O., Flynn, S., Brockway, E. T., Kaugars, K. E., Báldi, R., Ramikie, T. S., Çınar, R., Kunos, G., Patel, S., & Holmes, A. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.318 · Cited by 50
Demers, C. H., Drabant, E. M., Bogdan, R., & Hariri, A. R. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.021 · Cited by 52
Cannabinoids as therapeutics for PTSD
Sbarski, B., & Akirav, I. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107551 · Cited by 47
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies
Sloan, M. E., Grant, C. W., Gowin, J. L., Ramchandani, V. A., & Foll, B. L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0081-z · Cited by 47
Nia, A. B., Bender, R. L., & Harpaz‐Rotem, I. (2019) · Chronic Stress · doi:10.1177/2470547019864096 · Cited by 48
Corticosterone effects induced by stress and immunity and inflammation: mechanisms of communication
Xu, J., Wang, B., & Ao, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1448750 · Cited by 54
Endocannabinoids and Acute Pain Following Total Knee Arthroplasty
Azim, S., Nicholson, J., Rebecchi, M., Galbavy, W., Feng, T., Reinsel, R., Volkow, N., Benveniste, H., & Kaczocha, M. (2015) · Pain · doi:10.1097/01.j.pain.0000460315.80981.59 · Cited by 37
Locci, A., & Pinna, G. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.014 · Cited by 42
Ney, L. J., Matthews, A. J., Hsu, C. K., Zuj, D. V., Nicholson, E., Steward, T., Nichols, D. S., Graham, B. M., Harrison, B. J., Bruno, R., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23170 · Cited by 43
Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns
Koenig, A. M., Gao, W., Umlauft, M., Schury, K., Reister, F., Kirschbaum, C., Karabatsiakis, A., & Kolassa, I. (2018) · Biological Psychology · doi:10.1016/j.biopsycho.2018.03.006 · Cited by 44
Ney, L. J., Felmingham, K. L., Bruno, R., Matthews, A. J., & Nichols, D. S. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114103 · Cited by 41
Wingenfeld, K., Dettenborn, L., Kirschbaum, C., Gao, W., Otte, C., & Roepke, S. (2018) · Stress · doi:10.1080/10253890.2018.1451837 · Cited by 43
Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies
Raymundi, A. M., da Silva, T. R., Sohn, J. M. B., Bertoglio, L. J., & Stern, C. A. J. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02813-8 · Cited by 43
The endocannabinoid system in the amygdala and modulation of fear
Gunduz‐Cinar, O. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110116 · Cited by 40
Cannabinoids and their therapeutic applications in mental disorders
Scherma, M., Muntoni, A. L., Riedel, G., Fratta, W., & Fadda, P. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/pfadda · Cited by 38
Gowatch, L. C., Evanski, J. M., Ely, S. L., Zundel, C. G., Bhogal, A., Carpenter, C., Shampine, M. M., O’Mara, E., Mazurka, R., Barcelona, J., et al. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0246 · Cited by 39
Investigational drugs under development for the treatment of PTSD
Ragen, B., Seidel, J., Chollak, C., Pietrzak, R. H., & Neumeister, A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1020109 · Cited by 37
Scheyer, A. F., Yasmin, F., Naskar, S., & Patel, S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01438-7 · Cited by 37
Cannabinoids: Revealing their complexity and role in central networks of fear and anxiety
Murkar, A., Koninck, J. D., & Merali, Z. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.09.002 · Cited by 35
Circulating endocannabinoids and affect regulation in human subjects
Coccaro, E. F., Hill, M. N., Robinson, L., & Lee, R. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.03.009 · Cited by 34
Self-citationAgorastos, A., Kellner, M., Baker, D. G., & Otte, C. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000079 · Cited by 33
Giacobbe, J., Marrocu, A., Benedetto, M. G. D., Pariante, C. M., & Borsini, A. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.12.024 · Cited by 36
Translation of animal endocannabinoid models of PTSD mechanisms to humans: Where to next?
Ney, L. J., Crombie, K. M., Mayo, L. M., Felmingham, K. L., Bowser, T. A., & Matthews, A. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.040 · Cited by 30
Circulating endocannabinoids and psychological outcomes in women with PTSD
Botsford, C., Brellenthin, A. G., Cisler, J. M., Hillard, C. J., Koltyn, K. F., & Crombie, K. M. (2022) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2022.102656 · Cited by 29
Self-citationXue, F., Xue, S., Liu, L., Sang, H., Ma, Q., Tan, Q., Wang, H., Zhou, C., & Peng, Z. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.018 · Cited by 30
Wyatt, R. M., Fraser, I. C., Welty, N., Lord, B., Wennerholm, M. L., Sutton, S. W., Ameriks, M. K., Dugovic, C., Yun, S., White, A., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.262139 · Cited by 30
Walther, A., Kirschbaum, C., Wehrli, S., Rothe, N., Penz, M. S., Wekenborg, M., & Gao, W. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110658 · Cited by 30
Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity-related Disorders
Tarragón, E., & Moreno, J. J. (2017) · Chemical Senses · doi:10.1093/chemse/bjx062 · Cited by 28
A review of the effects of acute and chronic cannabinoid exposure on the stress response
Glodosky, N. C., Cuttler, C., & McLaughlin, R. J. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100945 · Cited by 31
Rice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 33
Metadata
- Authors
- Hill, M. N., Bierer, L. M., Makotkine, I., Golier, J. A., Galea, S., McEwen, B. S., Hillard, C. J., & Yehuda, R.
- Affiliations
- University of Calgary (CA)
- James J. Peters VA Medical Center (US)
- Columbia University (US)
- Rockefeller University (US)
- Medical College of Wisconsin (US)
- Corresponding author
- Hill, Matthew N.
- Venue
- Psychoneuroendocrinology
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 38
- Issue
- 12
- Pages
- 2952-2961
- ISSN
- 0306-4530 (ISSN-L)
- PMC
- PMC3870889
- OpenAlex
- W2024564598
- Cited by
- 256
- References
- 56
- Citations by year
- 2026: 8 · 2025: 27 · 2024: 24 · 2023: 22 · 2022: 15 · 2021: 28 · 2020: 24 · 2019: 22 · 2018: 28 · 2017: 16 · 2016: 10 · 2015: 19 · 2014: 10 · 2013: 2
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychoneuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Mental Health (MH-41256, R37MH041256, R01MH041256, R56MH077321)
- National Institute on Drug Abuse (R01DA026996, DA026996)
- National Center for Research Resources (5 M01RR00071, M01RR000071)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- post-traumatic stress disorder, endocannabinoids, 2-arachidonoylglycerol, anandamide, cortisol, September 11 attacks, World Trade Center, intrusion symptoms, emotional memory, stress response, plasma biomarkers
- MeSH terms
- Aged, Alcoholism, Amides, Arachidonic Acids, Ethanolamines, Ethnicity, Female, Glycerides, Humans, Hydrocortisone, Male, Middle Aged, Neuropsychological Tests, Oleic Acids, Palmitic Acids, Psychiatric Status Rating Scales, Sex Characteristics, Stress Disorders, Post-Traumatic, Terrorism, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
